US Patent 8007791 Prevention and treatment of complement-associated eye conditions
Patent 8007791 was granted and assigned to Genentech on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+237 characters)
Article
Patent abstract
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08007791 Prevention and treatment of complement-associated eye conditions US Patent 8007791 Prevention and treatment of complement-associated eye conditions
Infobox
Patent Number
0800779100
Patent Number
800779100
Edits on 2 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080077910
Date of Patent
August 30, 2011
0Patent Application Number
121544660
Date Filed
May 22, 2008
0Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080077910
Date of Patent
August 30, 2011
0Patent Application Number
121544660
Date Filed
May 22, 2008
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08007791 Prevention and treatment of complement-associated eye conditions
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08007791
Date of patent
August 30, 2011
Patent application number
12154466
Date Filed
May 22, 2008
Patent primary examiner
Find more entities like US Patent 8007791 Prevention and treatment of complement-associated eye conditions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
